You are here:

aripiprazole IM (Abilify)

Advice

Following an abbreviated submission

aripiprazole intramuscular injection (Abilify) is accepted for use in NHS Scotland for the rapid control of agitation and disturbed behaviours in patients with schizophrenia when oral therapy is not appropriate.

Where aripiprazole is an appropriate antipsychotic, this new formulation provides rapid control of symptoms at an equivalent cost to solid oral dosage forms.

SMC has not recommended aripiprazole for use within NHS Scotland for the treatment of manic episodes in bipolar 1 disorder. Therefore this formulation is not recommended for the rapid control of agitation and disturbed behaviours in patients with manic episodes in bipolar 1 disorder.

Drug Details

Drug Name: aripiprazole IM (Abilify)
SMC Drug ID: 522/08
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd
Indication: For the rapid control of agitation and disturbed behaviours in patients with schizophrenia, when oral therapy is not appropriate
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 8 December 2008

Back